Formula Identification (FID) 114657 in Contact Lens Wearers
Launched by ALCON RESEARCH · Nov 17, 2014
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Must sign the informed consent form.
- • Stable, tear lipid layer thickness ≤ 75 nm without contact lenses.
- • Successfully wearing bi-weekly or monthly replacement soft contact lenses in both eyes for a minimum of 5 days/week during the past 2 months prior to Visit 1.
- • Vision correctable to 20/25 Snellen (feet) or better at distance with habitual contact lenses at Visit 1.
- • Willing to wear lenses 5 days a week, 8 hours a day for at least 2 days during the study.
- • Demonstrate symptoms of contact lens discomfort.
- • Other protocol-defined inclusion criteria may apply.
- Exclusion Criteria:
- • Routinely sleeping in lenses.
- • Any active eye inflammation or condition that contraindicates contact lens wear.
- • Any systemic diseases that could prevent successful contact lens wear.
- • Use of systemic or ocular medications that contraindicate lens wear.
- • Fit with only 1 contact lens.
- • Unwilling to discontinue the use of cosmetics (such as eyeliner, mascara, or eye shadow) or facial creams on or around the eyelids on Day 1 and Day 14 of the study.
- • Women of childbearing potential who are currently pregnant, test positive for pregnancy at Screening visit, breast feeding, or unwilling to use adequate birth control throughout the study.
- • Other protocol-defined exclusion criteria may apply.
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Clinical Manager, Pharmaceuticals, Global Medical Affairs
Study Director
Alcon Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials